title: Targeting the Inactive Conformation of JAK2 in Hematological Malignancies.
abstract: Activating JAK2 mutants cause hematological malignancies. Current clinical type I JAK2 inhibitors effectively relieve symptoms but fail to resolve the disease. In this issue of Cancer Cell, two articles by Wu and colleagues and Meyer and colleagues characterize a type II JAK2 inhibitor that is effective in preclinical models of JAK2-dependent myeloproliferative neoplasms and B cell acute lymphoblastic leukemia.
authors.affiliation: School of Medicine, University of Tampere, Biokatu 8, 33014 Tampere, Finland; Clinical Hematology, Department of Internal Medicine, Tampere University Hospital, Medisiinarinkatu 3, 33520 Tampere, Finland. Electronic address: olli.silvennoinen@uta.fi.
authors.forename: Olli
authors.initials: O
authors.lastname: Silvennoinen
authors.affiliation: Kimmel Center for Biology and Medicine at the Skirball Institute and Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, 540 First Avenue, New York, NY 10016, USA.
authors.forename: Stevan R
authors.initials: SR
authors.lastname: Hubbard
mesh_terms: D000631:Aminopyridines / Q000008:administration & dosage*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage*; D003907:Dexamethasone / Q000008:administration & dosage*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors* / Q000235:genetics*; D009196:Myeloproliferative Disorders / Q000188:drug therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*
chemical_list: D000631:Aminopyridines; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D047428:Protein Kinase Inhibitors; D003907:Dexamethasone; D053614:Janus Kinase 2